Involving Iga, Igd, Ige, Or Igm Patents (Class 436/513)
  • Patent number: 11099179
    Abstract: The present invention relates to a device and a method for detecting substances which are present in biological or chemical samples, each substance producing an optically detectable signal upon reaction with a reagent. The device further comprises a sample carrier with at least two receptacles for receiving samples and is characterized in that at least part of the receptacle is equipped to receive at least 2 reagents each, and in that a camera for recording an image which shows at least one receptacle filled with at least two reagents for the detection of different substances, and an evaluation device for evaluating the samples which device is designed such as to evaluate each image by analyzing the signals in the image.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 24, 2021
    Inventor: Torsten Matthias
  • Patent number: 11099178
    Abstract: The present invention relates to a device and a method for detecting substances which are present in biological or chemical samples, each substance producing an optically detectable signal upon reaction with a reagent. The device further comprises a sample carrier with at least two receptacles for receiving samples and is characterized in that at least part of the receptacle is equipped to receive at least 2 reagents each, and in that a camera for recording an image which shows at least one receptacle filled with at least two reagents for the detection of different substances, and an evaluation device for evaluating the samples which device is designed such as to evaluate each image by analyzing the signals in the image.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: August 24, 2021
    Inventor: Torsten Matthias
  • Patent number: 10921319
    Abstract: The present invention relates to a detection device for safe and convenient immunoassay of an analyte containing pathogens.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 16, 2021
    Assignee: Great North Research And Innovation Ltd
    Inventor: Georgios Gerardos
  • Patent number: 10845362
    Abstract: The application provides competition assays used to detect free-light chains or intact immunoglobulins comprising incubating the sample with anti-FLC antibody, or heavy chain class-light chain type-specific antibodies, or fragments of such antibodies, and a known amount of FLC or intact immunoglobulin and detecting the binding of the antibody to the known amount of FLC or immunoglobulin. Assay kits and methods of producing particles coated with FLC are also provided.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: November 24, 2020
    Assignee: THE BINDING SITE GROUP LIMITED
    Inventors: Graham Peter Mead, Hugh Carr Smith, Arthur Randall Bradwell
  • Patent number: 10823694
    Abstract: A method for detecting a presence and/or a concentration of a target substance in a reagent solution using enzyme-linked immunosorbent assay (ELISA) includes binding the target substance directly or indirectly to an electrode, and binding a detection agent directly or indirectly to the bound target substance. The method further includes modulating a pH of only a portion of the reagent solution in which the bound target substance and the bound detection agent are located using the electrode, the modulated pH of the portion of the reagent solution causing the bound detection agent to undergo a change, and detecting the change in the bound detection agent. The detected change corresponds to the presence of the target substance in the reagent solution and/or the concentration of the target substance in the reagent solution.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: November 3, 2020
    Assignee: Robert Bosch GmbH
    Inventors: Young Shik Shin, Nadezda Fomina, Christopher Johnson, Christoph Lang, Patrick Staley
  • Patent number: 10379046
    Abstract: The present invention is directed to a novel method to multiplex long lifetime fluorescent dyes using time-resolved fluorescence (TRF) detection. A combination of spectral and temporal differences in fluorescence emission is used to enhance the ability to separate signals in an assay from multiple dyes. Multiplexed TRF detection apparatuses and systems configured for performing all or part of any of the methods disclosed herein are also provided, particularly apparatuses and systems incorporating cartridge-based multi-mode readers.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: August 13, 2019
    Assignee: Molecular Devices, LLC
    Inventors: Michael Katzlinger, Evan F. Cromwell, Vanitha Thulasiraman
  • Patent number: 9377456
    Abstract: Various devices, systems and methods for determining a parameter of and/or detecting chemical and biological substances in bodily fluid are described herein. A device or system may include a substrate. An active sensor having an electrical characteristic and/or a control sensor may be disposed on the substrate. In certain variations, a differential between a first signal from the active sensor, and a second signal from the control sensor may be used to determine a parameter of the chemical or biological substance in the sample of bodily fluid.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: June 28, 2016
    Assignee: Avails Medical, Inc.
    Inventors: Meike Herget, Oren S. Knopfmacher
  • Patent number: 9243045
    Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 26, 2016
    Assignee: PHADIA AB
    Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
  • Patent number: 9217223
    Abstract: The present invention is directed towards a method for preparing and/or treating a fluid and/or moister absorbing basic material (1), illustrated as a textile soft material, to form an allergen or allergens impregnated material (2).
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: December 22, 2015
    Inventor: Patrick Johan Olof Ermes Mannius Zu Dem Berge
  • Patent number: 9182401
    Abstract: The use of the IRAP protein for implementing methods of diagnosis and of prognosis.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: November 10, 2015
    Assignee: UNIVERSITE JOSEPH FOURIER
    Inventor: Serge Bottari
  • Patent number: 9151747
    Abstract: Kits and methods detect sucralose or determine sucralose concentration in a sample by using polyclonal or monoclonal anti-sucralose antibodies. An ELISA assay or other immunoassay detects sucralose or determines sucralose concentration in various samples.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 6, 2015
    Assignee: Mercyhurst University
    Inventor: Amy D. Parente
  • Patent number: 9119866
    Abstract: The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: September 1, 2015
    Inventor: Huiru Wang
  • Patent number: 9034657
    Abstract: A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, a
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 19, 2015
    Assignee: Phadia AB
    Inventors: Gerd Rundström, Per Matsson, Paul Christopher
  • Patent number: 9012372
    Abstract: The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is a higher-level regulator for STAT-6 and BCL-6, the regulator being specific for IgE production in B-cells by amplifying the effect of STAT-6 and antagonizing the effect of BCL-6. The inventors have observed no influence of SWAP-70 on the expression of other genes that are likewise regulated by STAT-6 and/or BCL-6. In summary, it can be concluded that SWAP-70 positively regulates IgE production by shifting the interaction of the two antagonists STAT-6 and BCL-6 with regulatory elements of the IgE gene in favor of the activator STAT-6. Based on said findings, the invention provides a screening method which allows for identifying novel active agents that specifically inhibit IgE production.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 21, 2015
    Assignee: Albonia Biotech, Inc.
    Inventors: Rolf Jessberger, Tatsiana Audzevich
  • Patent number: 8993346
    Abstract: Provided herein is a new hybrid material system, mCNT, including magnetic carbon nanotubes for biological and medical sensing applications. In certain embodiments, the systems include magnetic material on the interior of carbon nanotubes (CNTs). The amount of magnetic particles inside CNTs may be such that mCNT can respond to small, low cost, portable magnet. The exterior CNT surface is kept intact for biomolecular attachments or other functionalizations. Performance enhancement with this novel material includes improved sensitivity, reduced response time, and reduced sample volume. According to various embodiments, the mCNTs are substrates for the adherence of molecules participating in these assays or as active sensing elements. Also provided are methods of fabricating two-dimensional mCNT and CNT networks on printed electrodes.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: March 31, 2015
    Assignee: Nanomix, Inc.
    Inventors: Ray Radtkey, Kanchan Joshi, Bradley N. Johnson, Ying-Lan Chang
  • Patent number: 8962264
    Abstract: The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment. The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: February 24, 2015
    Assignees: National University Corporation University of Fukui, JNC Corporation
    Inventor: Sakon Noriki
  • Patent number: 8956859
    Abstract: A host antigen-specific antibody testing system and method. The a ternary complex of the antigen, a ligand-bound anti-host IgM, and a non-host anti-antigen IgG detector conjugate selectively form a quaternary complex with host antibodies, wherein the host antibodies and IgG compete for the antigen, and the IgM binds the host antibodies. The quaternary complex is retained by an immobilized IgM ligand binding agent, and any residual ternary is retained by a later encountered immobilized anti-non-host IgG. If sufficient host antibodies have a high affinity for the antigen, the complex is detected at the quaternary complex detection region based on the presence of the detector, and if there are insufficient high affinity host antibodies, the ternary complex migrates past the quaternary complex detection region and is retained and detected at a control region.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: February 17, 2015
    Assignee: Aviex Technologies LLC
    Inventor: David G. Bermudes
  • Patent number: 8956823
    Abstract: An anti-antibody reagent for use in a competitive or sandwich simplex or multiplex assay, said reagent comprising one or more labeled anti-antibodies for the primary antibodies to be determined in the assay, the reagent further comprising a corresponding unlabeled anti-antibody in an excess or near excess concentration with respect to their binding partners.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 17, 2015
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: William F. Link, Renato B. Del Rosario, Randy Sweet, David L. King
  • Patent number: 8951806
    Abstract: The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g., an enzyme, fluorescent or direct label, etc.) wherein the conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e., which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: February 10, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventor: Juergen Klepp
  • Patent number: 8932877
    Abstract: Disclosed are photoluminescent particles. The particles include a core nano-sized particle of carbon and a passivation agent bound to the surface of the nanoparticle. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the photoluminescent carbon nanoparticles can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: January 13, 2015
    Assignee: Clemson University Research Foundation
    Inventor: Ya-Ping Sun
  • Patent number: 8921121
    Abstract: A chemiluminescence-based detection system and method for counting blood cells by capturing and isolating target blood cells flowing through a microfluidic chip and detecting light emitted by the captured target blood cells.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: December 30, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Zuankai Wang, Sau Yin Chin, Samuel K. Sia
  • Patent number: 8828738
    Abstract: The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 ?g/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 9, 2014
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, John Emegbero Omakor
  • Patent number: 8809005
    Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: August 19, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Patent number: 8765641
    Abstract: An antibody microarray screen including a substrate, monoclonal and polyclonal antibodies that are purified immunoglobins, wherein the antibodies are spotted on predetermined positions on the substrate, and fluids unprocessed for immunoglobulin isolation (e.g., anti-sera, ascites fluids, or hybridoma culture media), wherein the unprocessed fluids are spotted on the predetermined positions on the substrate. Production of drug-metabolizing enzyme antibody microarrays containing closely related cytochromes P450 is disclosed. Methods of manufacturing an antibody microarray, an internal control molecule for use in an antibody microarray, a method of determining optimal spotting concentrations of IgG and a method to increase a detectable signal with microarray analysis are disclosed.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: July 1, 2014
    Assignee: Detroit R&D, Inc.
    Inventors: Hyesook Kim, Alan A. Dombkowski, Raymond F. Novak, Brian B. Haab
  • Patent number: 8716031
    Abstract: Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: May 6, 2014
    Assignees: RIKEN, Animal Allergy Clinical Laboratories
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Nobutaka Yasuda
  • Patent number: 8716032
    Abstract: The present invention is to provide an immunochromatography method which is capable of performing a detection with high-sensitivity or reduced false-positives by suppressing the occurrence of false-positive when a signal is amplified. An immunochromatography method includes in a state of where a complex of a test substance and a labeling substance containing a metal coupled with a first binding substance for the test substance is formed, developing the complex on an insoluble carrier in presence of a protease hydrolyzate of protein; capturing the test substance and the labeling substance at a detection site of the insoluble carrier containing a material which has a binding property to the first binding substance for the test substance or a second binding substance for the test substance; and detecting the test substance by amplifying the labeling substance captured.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: May 6, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Junichi Katada, Hiroyuki Chiku
  • Patent number: 8709791
    Abstract: A biosensor combining the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In a preferred embodiment, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV). Rapid detection of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, and the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1 The biosensor was able to delect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS).
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: April 29, 2014
    Assignees: STC.UNM, Sandia National Laboratories
    Inventors: Richard S Larson, Brian Hjelle, Pam R Hall, David C Brown, Marco Bisoffi, Susan M Brozik, Darren W Branch, Thayne L Edwards, David Wheeler
  • Patent number: 8679858
    Abstract: Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: March 25, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Garry P. Nolan, Erin F. Simonds, Sean C. Bendall
  • Patent number: 8663985
    Abstract: An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: March 4, 2014
    Assignee: Miltenyi Biotec GmbH
    Inventors: Stefan Miltenyi, Susanne Hoher-Peters, Monika Winkels
  • Patent number: 8647889
    Abstract: The present invention is directed to a luminescent immunoassay method for detecting an analyte in a liquid sample with high sensitivity. The invention provides a unique combination of (i) using a probe having a small sensing surface area for binding analyte molecules, (ii) using a high molecular weight branched polymer conjugated with multiple binding molecules and multiple luminescent labels, and (iii) cycling the probe having immunocomplex formed back to the reagent vessel and amplification vessel 1-10 times and repeating the reaction with the reagent and the amplification polymer, to improve the sensitivity of detection level. For each cycling, the luminescent signal is increased significantly over the noise.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: February 11, 2014
    Assignee: Access Medical Systems, Ltd.
    Inventors: Robert F. Zuk, Hong Tan
  • Patent number: 8647888
    Abstract: An immunoassay test strip includes a sample pad for receiving a liquid patient sample; a conjugate pad fluidly coupled to the sample pad, wherein the conjugate pad contains a substantially uniform application of conjugate reagent; a contact pad fluidly coupled to the conjugate pad; a porous or bibulous member, e.g., made from nitrocellulose, fluidly coupled to the contact pad which is capable or transporting a liquid sample along the test strip, wherein the porous or bibulous member serves as the solid support upon which immunoreactions occur, and an absorbent pad fluidly coupled to the porous or bibulous member, which serves to draw sample fluid introduced onto the sample pad through the respective conjugate pad, contact pad and porous or bibulous member.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 11, 2014
    Assignee: Hologic, Inc.
    Inventor: Lina Baydoun
  • Patent number: 8609432
    Abstract: Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 17, 2013
    Inventors: Ronald Joseph Harbeck, Karen Mary Andrews, Donald MacGlashan
  • Patent number: 8609433
    Abstract: A sample compressor applies pressure to a sample collector and a sample application zone of a test strip to transfer a sample from the sample collector and a binding partner of an analyte to the sample application zone in a lateral flow device. At least one of the binding partners of the analyte is not located on the test strip prior to use of the lateral flow device. The test strip may be a universal test strip with no molecule that specifically binds the analyte is located on the test strip. The sample compressor may be a universal sample compressor also with no molecule that specifically binds the analyte on the sample compressor. The lateral flow device may also include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: December 17, 2013
    Assignee: Rapid Pathogen Screening, Inc.
    Inventors: Robert P. Sambursky, Uma Mahesh Babu, Robert W. VanDine, Ganga V. Kanaujia, Thomas Orsini
  • Patent number: 8580530
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8580531
    Abstract: The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies, said antigenic molecules carried by the erythrocytes consisting of antigenic molecules carried not only by the erythrocytes, but also by at least one other cell population, other than the blood group antigen molecules, said method comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes or erythrocyte membrane fragment.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 12, 2013
    Assignee: Bio-Rad Innovations
    Inventors: Frederic Buffiere, Yves Raisin, Eliane Rivalin, Amparo Sanjuan
  • Patent number: 8557603
    Abstract: Provided herein are synthetic peptides, methods and kits for easy detecting or diagnosing an autoimmune disease, particularly, Henoch-Schönlein purpura (HSP), based on the detection of autoimmune antibodies with peptides derived from ?-2-glycoprotein-1 (?2-GPI).
    Type: Grant
    Filed: January 2, 2009
    Date of Patent: October 15, 2013
    Assignee: FlySun Development Co. Ltd.
    Inventors: Bor-Luen Chiang, Yao-Hsu Yang, Chung-Sheng Huang
  • Patent number: 8501495
    Abstract: A sequential solid phase immunoassay and system is disclosed. The immunoassay utilizes the secondary antibody method for the detection of antibodies in a membrane-based test. The system comprises a test strip including a nitrocellulose membrane having an immobilized antigen in a capture zone on the membrane and a stabilized liquid secondary antibody conjugate. The sequential solid phase immunoassay is performed in a sequential manner with the addition of a fluid specimen being followed by the addition of the stabilized liquid secondary antibody conjugate. The sequential procedure using the system includes allowing the fluid specimen containing antibodies specific to the antigen to pass laterally from the test strip first end through the capture zone. The immobilized antigens in the capture zone capture antibodies specific to the antigen. The stabilized liquid secondary antibody conjugate then binds to the captured antibodies and can be detected visually or by a machine or reader.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: August 6, 2013
    Assignee: Equal Access to Scientific Excellence
    Inventors: Kai Ling Yao, Peter Chun
  • Patent number: 8497138
    Abstract: In one aspect the present invention provides a method for selecting a cell or cell colony which produces a polypeptide of interest, comprising a) providing a medium comprising cells and a detection agent, wherein the detection agent is associated with a detectable signal and the detection agent is capable of binding to the polypeptide of interest; b) providing a solid phase having a capture agent disposed thereon, wherein the capture agent is capable of binding to the polypeptide of interest; c) contacting the medium with the solid phase; d) detecting the signal associated with the detection agent; and e) selecting a cell or cell colony associated with the signal, wherein presence of the signal is indicative of a cell or cell colony which produces the polypeptide of interest.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: July 30, 2013
    Assignee: Genetix Limited
    Inventors: Julian Burke, Alasdair Robertson, Xiao Zhang
  • Patent number: 8486645
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 16, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8486721
    Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: July 16, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8450074
    Abstract: A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: May 28, 2013
    Inventor: W. Jean Dodds
  • Patent number: 8450072
    Abstract: A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: May 28, 2013
    Inventor: W. Jean Dodds
  • Patent number: 8426210
    Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: April 23, 2013
    Assignee: New York Blood Center, Inc.
    Inventor: Gregory R. Halverson
  • Patent number: 8404456
    Abstract: The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 26, 2013
    Assignee: AbSorber AB
    Inventors: Jan Holgersson, Jining Liu, Linda Lindberg, Per Grufman
  • Patent number: 8404820
    Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: March 26, 2013
    Assignee: Medarex, Inc.
    Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
  • Patent number: 8394325
    Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: March 12, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8389293
    Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in competitive analyte immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads opsonized for leukocytes; and (b) performing a competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: March 5, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Graham Davis
  • Patent number: 8377669
    Abstract: The invention is directed to methods and devices for reducing interference from leukocytes in an analyte immunoassay, and in particular in non-competitive immunoassays. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with sacrificial beads; and (b) performing a non-competitive immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG-coated sacrificial beads.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: February 19, 2013
    Assignee: Abbott Point of Care Inc.
    Inventors: John Lewis Emerson Campbell, Adam Roger Moss, Graham Davis
  • Patent number: 8338117
    Abstract: The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (?2-GPI) as an indicator for atherosclerosis.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 25, 2012
    Assignee: Inova Diagnostics, Inc.
    Inventors: G. Michael Iverson, Walter L. Binder, Gary L. Norman
  • Patent number: RE43979
    Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.
    Type: Grant
    Filed: February 5, 2003
    Date of Patent: February 5, 2013
    Assignee: Abbott Laboratories
    Inventors: Oystein Fodstad, Gunnar Kvalheim